Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 3/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.34 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.34 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.34 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2909444 | 1.00 | CA1 (0.59) | CA1CA2PTGS1CES2MGLL | |
| SCHEMBL2352948 | 0.81 | CA1 (0.57) | CA1CA2MGLL | |
| SCHEMBL3317126 | 0.81 | CA1 (0.57) | CA1CA2MGLL | |
| SCHEMBL542321 | 0.79 | CA1 (0.89) | CA1CA2PTGS1MGLLAHR | |
| SCHEMBL38660141 | 0.79 | CA1 (0.45) | CA1CA2PTGS1MGLLCYP1A2 | |
| SCHEMBL542320 | 0.79 | CA1 (0.89) | CA1CA2PTGS1MGLLAHR | |
| SCHEMBL28879159 | 0.75 | PTGS1 (0.41) | CA1CA2PTGS1CES2MGLL | |
| SCHEMBL28879158 | 0.75 | PTGS1 (0.41) | CA1CA2PTGS1CES2MGLL | |
| SCHEMBL16734811 | 0.73 | CA1 (0.36) | CA1CA2PTGS1RPS6KA3JAK3 | |
| SCHEMBL31416502 | 0.73 | CA1 (0.53) | CA1CA2PTGS1MGLLNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110229437-A | A kind of modified PVC CABLE MATERIALS and preparation method thereof | 周宁东 | 2019-09-13 | — | — | CN | claimed |
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | DONG-A ST CO., LTD. (KR) | 2025-09-11 | — | — | US | disclosed |
| EP-4514780-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | Dong-A ST Co., Ltd. (KR) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023209651-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | DONG-A ST CO., LTD. (KR) | 2023-11-02 | — | — | WO | disclosed |
| CN-110229437-A | A kind of modified PVC CABLE MATERIALS and preparation method thereof | 周宁东 | 2019-09-13 | — | — | CN | disclosed |
| CN-110229437-A | A kind of modified PVC CABLE MATERIALS and preparation method thereof | 周宁东 | 2019-09-13 | — | — | CN | disclosed |
| EP-2215043-B1 | CARBON LINKED MODULATORS OF Y-SECRETASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-06 | — | — | EP | disclosed |
| EP-2215043-A1 | CARBON LINKED MODULATORS OF Y-SECRETASE | Janssen Pharmaceutica, N.V. (BE) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009052334-A1 | CARBON LINKED MODULATORS OF Y-SECRETASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
| US-20090105288-A1 | CARBON LINKED MODULATORS OF gamma-SECRETASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105288-A1 | CARBON LINKED MODULATORS OF gamma-SECRETASE | BACE1, BACE2, PSEN1 | CA1 48/4885CA2 1202/4885PTGS1 1614/4885 |
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | TEAD1, TEAD2, TEAD3 | CA1 576/4885CA2 881/4885PTGS1 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.